๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation

โœ Scribed by Hankey, G. J.; Stevens, S. R.; Piccini, J. P.; Lokhnygina, Y.; Mahaffey, K. W.; Halperin, J. L.; Patel, M. R.; Breithardt, G.; Singer, D. E.; Becker, R. C.; Berkowitz, S. D.; Paolini, J. F.; Nessel, C. C.; Hacke, W.; Fox, K. A. A.; Califf, R. M.

Book ID
121810629
Publisher
Lippincott Williams and Wilkins
Year
2014
Tongue
English
Weight
920 KB
Volume
45
Category
Article
ISSN
0039-2499

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Letter by Apostolakis et al Regarding Ar
Letter by Apostolakis et al Regarding Article, โ€œRenal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohortsโ€
โœ Apostolakis, Stavros ;Lane, Deirdre A. ;Banerjee, Amitava ๐Ÿ“‚ Article ๐Ÿ“… 2013 ๐Ÿ› Lippincott Williams and Wilkins ๐ŸŒ English โš– 419 KB
Rationale and design of the eXplore the
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
โœ Ezekowitz, Michael D.; Cappato, Riccardo; Klein, Allan L.; Camm, A. John; Ma, Ch ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 196 KB